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Summary: This study was carried out on 625 newborns delivered between July 1993 and December 1994 and 221
children visiting the clinic in the first year of life using an immunoluminometric assay specific for apolipoprotein(a),
but calibrated with lipoprotein(a), hence the use of the term (apo)lipoprotein(a) for neonatal values. (Apo)lipopro-
tein(a) concentrations were measured in 278 neonates over the first 12 days of life (median observation time 6
days). A further 64 children were followed up over a period of 1 —10 months (median observation time 5 months).
The median (apo)lipoprotein(a) concentration at birth was 14.7 mg/1 (males 14.6, females 14.7 mg/1). The range of
concentrations measured was between 1 and 433 mg/1. The correlation coefficient between maternal and neonatal
lipoprotein(a) at birth was 0.509 for 483 data pairs.
The behaviour of serum concentrations of (apo)lipoprotein(a)
— during the first days of life varied greatly and was independent of the birth level. Eighty-four babies showed a
decrease, 107 an increase and 87 no change in (apo)lipoprotein(a) levels;
— over the first months of life was more unified with 50 children showing an increase in serum lipoprotein(a), a
decrease in 4 cases and no change in 10 cases. In these 64 children the median increase in serum (apo)lipoprotein(a)
was from 15.8 ing/1 at birth (range 1 to 364 mg/1) to 38.5 mg/1 at 6 months.
The median lipoprotein(a) concentrations in the children under 1 year (median age 6 months) was 37.0 mg/1 (males
37.1, females 37.0 ing/1).
The results showed that it is possible to evaluate the risk of elevated lipoprotein(a) levels by comparing the
concentrations at birth, or within the first week of life, and after 6 months. A single measurement at birth was not
able to be used as a predictor. In cases where (apo)lipoprotein(a) concentrations rose rapidly in the 10 days after
birth, the values at 6 months of age all lay in the the upper quartile of results from children of the same age group.
UC |0n months after birth (1, 4). This report covers the time
Although several reports on lipoprotein(a) concentra- period between birth and the end of the first year of
tions at birth have been published (1—5), only a few life. The observation period has been split into three
have followed the course of development of serum parts: from birth over the first 12 days of life and
concentrations of this analyte over the first weeks and between the first and tenth month of life on single
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children, and from isolated oBservations over the first
12 months of life.
Observations were made at birth on cord and capillary
blood as well as in the serum or plasma of the mother.
Comparisons were made on a limited number of samples
between the apolipoprotein(a) and lipoprotein(a) con-
centrations at birth using specific assays designed to
measure each analyte.
The aim of the study was to establish reference ranges
for (apo)lipoprotein(a) in newborns and small children,
to study the changes in serum concentrations over the
first 12 months of life and to see whether it is possible
during this time to predict whether a child will develop
pathologically high levels of lipoprotein(a) in serum.
In addition, data from studies on hospitalised adults and
children between the age of 1 and 17 years have been
included to support the view that it is possible to predict
children at risk within the first six months of life.
Materials and Methods
Subjects studied and data used
Six-hundred-twenty-five newborns delivered between August 1993
and December 1994 in Stralsund were included in the study. This
included over 98% of all births in the town. In addition 221 chil-
dren under one year of age of attending the childrens' hospital and
who had blood taken for routine testing formed part of the study.
The mothers of 483 newborns formed the basis of the comparison
of serum lipoprotein(a) concentrations between mother and child
at birth. For the development of lipoprotein(a) concentrations dur-
ing life, data from 1105 children between the age of 1 and 17 years
and 918 adults between the age of 18 and 93 years were used as
a basis.
The period of investigation on individuals was concentrated on the
perinatal period, the first 12 days of life and the first 10 months of
life. A total of 709 individual observations were made on the 278
children in the first 10 days of life and 151 observations in the 64
children during the first 10 months of life.
Methodology
Apolipoprotein(a) and lipoprotein(a) were measured as previously
published in this journal (6) using immunoluminometric assays and
a single lot of reagents and standards. The assays used polyclonal
antibodies, the solid-phase antibody being specific for apolipopro-
tein(a) and the liquid phase sandwich antibody for either apolipo-
protein B or apolipoproteui(a) respectively. Both serum and plasma
could be used as sample.
The assay with both antibodies directed against apolipoprotein(a)
was used in all cases except for one small comparison study in
which the lipoprotein(a) concentration was also measured in new-
boms using a liquid phase antibody directed against apolipoprotein
B. The standard used was calibrated against lipoprotein(a) (Im-
muno, Heidelberg, Germany) and contained the apolipoprotein
phenotype F/B. The choice of the antibody pair against apolipopro-
tein(a) was made to exclude any possible effects on the assay due
to the maturation of apolipoprotein B synthesis over the first 7
days of life (1).
The term (apo)lipoprotein(a) has been chosen for use in neonates
as it has been shown (see results) that assay designed to measure
lipoprotein(a), i. e. with a liquid-phase antibody direct against apo-
lipoprotein B, gave lower results than the assay designed to mea-
sure the apolipoprotein(a) molecule. After the first month of life,
there were no significant differences between values obtained'faith
both assays, so that the results were given in terms of lipoprotein(a)
in all groups. This was done to allow for comparison with earlier
results, and to a limited extent, with results from other groups who
normally express their results in terms of lipoprptein(a), regardless
as to whether the liquid-phase antibody is directed against apolipo-
protein(a) or apolipoprotein B.
Statistics
Non-parametric statistics were used throughout, as the distribution
of apolipoprotein(a) in serum was highly skewed (mean:median
> 2.4). The median was used as point of central tendency, relevant




Mother - Lp(a) [mg/l]
1000 10000
?5l ^Catteißram of 483 data pairs showing the relationship be- median maternal lipoprotein(a) value was 101 mg/l, for the
tween maternal and neonatal hpoprotein(a) concentrations at birth, nates 14.9 mg/l
The data are correlated with a correlation coefficient of 0.509 The
neo-
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Results
(Apo)lipoprotein(a) concentrations at birth
The median (apo)lipoprotein(a) concentration at birth
was 14.6 mg/1 for boys (n = 321) and 14.7 mg/1 for girls
(n = 304). The range of concentrations found was be-
tween 1 and 433 mg/1. The median age of the mothers
was 26 years and their median apolipoprotein(a) concen-
tration was 100 mg/1. The median gestational age was
39 weeks. Figure 1 shows the correlation between ma-
ternal and neonatal lipoprotein(a) concentrations in se-
rum and cord blood in 483 cases. The correlation coeffi-
cient of 0.509 is in accordance with that expected from
an autosomal codominant inheritance. Previous data
showed the excellent correlation between cord blood
and capillary blood (5). In 105 newborns the correlation
coefficient was 0.931, the regression equation log (capil-
lary blood) = 0.915 X log (cord blood) + 0.118 so that
either material could be used. Discrepancies were some-
times found where the difference between maternal and
neonatal concentrations were extreme (5). There was no
correlation between lipoprotein(a) levels and birth
weight, a point also noted by Wang et al. (3). Concentra-
tions of lipoprotein(a) were lower, when measured with
the assay with the liquid phase antibody directed against
apolipoprotein B. In a limited study on 46 samples at
birth, the median lipoprotein(a) concentration from the
assay using the liquid-phase antibody directed against
apolipoprotein(a) was 17.4 mg/1 (range 1.4-67.1 mg/1),
from the assay using the antibody to apolipoprotein B
13.1 mg/1 (range 1.1-59.3 mg/1). Whether or not these
differences are of clinical significance or relevance will
be seen in a larger prospective study at present being
carried out.
Behaviour of (apo)lipoprotein(a)
concentrations during the first days of life
Table la shows the distribution and tendency of (apo)li-
poprotein(a) concentrations during the first days (me-
dian observation period 6 days, range 2—12 days) and
months (median observation period 6 months, range
Tab. la Development of lipoprotein(a) [Lp(a)] over the first year of life in 342 infants
Development over the first 12 days of life (median observation time —6 days)
Lp(a) at birth Child (1) Mother Child (2) Quotient Difference


































-: 51 +: 40 nc
-: 28 +: 28 nc
-: 19 + : 10 nc
-: 9 +: 9 nc
1-364 mg/1 64 15.8 136 38.5 2.73 13.6 4 -: 50 + : 10 nc
Key to Table:
Child (1) - Lp(a) value at birth [mg/1];
Child (2) — Lp(a) value on the last day of observation [mg/1]
Mother - Lp(a) at parturition [mg/1].
All values are median values
Quotient - Median from all single quotient values
[Child (2) / Child (1)];
Difference — Median from all single difference values
[Child (2) - Child (1)] [mg/1]
Tendency — + denotes increase of more than 20% : — denotes
decrease of more than 20% : nc denotes no change
Tab. Ib Distribution of lipoprotein(a) concentrations (in mg/1) at birth compared with those at a









































































* In Groups (d) and (e) the 2.5 and 97.5 percentiles were replaced by the 5th and 95th percentiles, as
the number of data was too small for the former.
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Fig. 2a Median values of lipoprotein(a) concentrations during the
first 10 days of life. The groups are defined as in table la. Birth
levels <10 mg/1 (-O-), 10-25 mg/1 (-+-), 25-50 mg/1
(-*-).
1 2 3 4 6 6 7 8
Days of life
Fig. 2b The trend of lipoprotein(a) concentrations during the
week after birth is shown for 12 cases selected to show all possible
trends seen within the first 10 days of life.
1-10 months) of life. The fact that on average, the ba-
bies with lower concentrations came from mothers with
lower lipoprotein(a) concentrations is also reflected in
figure 1. Table Ib shows the distribution of (apo)lipo-
protein(a) concentrations at birth and after a median ob-
servation period of 6 days in the groups shown in ta-
ble 1.
The overall tendency of serum lipoprotein(a) levels over
the first days of life was not uniform with increases in
107 cases, decreases in 84 cases and no change in 87
cases. A change was defined as a decrease or increase
of over 20% when compared with the level at birth. The
median (apo)lipoprotein(a) concentrations over the first
10 days of life are shown in figure 2a, again using three
of the groups from table la. Due to insufficient data, the
group of neonates with (apo)lipoprotein(a) levels above
50 mg/1 at birth was not included.
Figure 2b shows individual cases which typify the de-
velopment of serum (apo)lipoprotein(a) levels in the
early post-natal period.
The cases showing a decline after birth may be associ-
ated with the cessation of placental transfer of (apo)lipo-
protein(a) from the mother. In all cases where a sharp
decrease in concentration was observed, there was a
large difference between maternal (high) and neonatal
(low) lipoprotein(a) concentrations. This was however
not always the case, as many mothers with high lipopro-
tein(a) levels gave birth to babies with low (apo)lipopro-
tein(a), but whose levels remained constant or rose after
birth, so that placental transfer may only occur in cer-
tain cases.
The quotient between last observation and birth (apo)li-
poprotein(a) concentrations showed a median change in
concentration between -8 and +34%, representing an
absolute median concentration change between —1.4
and +1.7 mg/1 (difference column in table la). The in-
teresting point to note is that the development of (apo)li-
poprotein(a) concentrations in serum over the first few
days of life was virtually independent of the birth -tevels
as seen in figure 2a, although the spectacular increase
were more often noted in the groups with concentrations
above 25 mg/1 at birth, as can be seen in the change in
distribution of concentrations in table Ib and the trends
for individual babies in figure 2b.
Development of lipoprotein(a) concentrations
during the first months of life
Table la also shows the results from 64 newborns who




Fig. 3 As for figure 2b, but showing the
tein(a) over the first 9 months of life for
parental values in each case were:
Case 1 (-·-)
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Fig. 4 Scattergram showing lipoprotein(a) concentrations in year of life. The children had no known lipid disorder at the time
young children between the ages of 2 weeks and 1 year. Samples of admission,
came from children who were admitted to hospital during the first
suits were either obtained from babies attending the
clinic for diverse reasons, or from routine check-ups be-
; tween 5 and 7 months of age. None of the children was
known to have a lipid disorder at the time.
The results here are more uniform with 50 children
showing an increase in serum lipoprotein(a), 4 a
decrease and no change in a further 10 cases. The me-
dian increase seen was. from 16.8 to 37.4 mg/1 represent-
ing a median percentage change of 144%. Figure 3
shows 6 individual cases.
Results from a further 221 children who attended the
childrens' hospital during the first year of life serve as
a control for the general development of lipoprotein(a)
levels and are shown as a scattergram in figure 4. The
median levels of lipoproteiii(a) in serum in both the 64
children who were individually followed up and the 221
children who had a single determination were compar-
able with 38.5 mg/1 and 37.0 mg/1 respectively, showing
that the samples were most probably taken from popula-
tions with the same characteristics, thus allowing com-
parisons to be made.
Additional data used for comparative and
extrapolative purposes
Figure 5a shows the distribution of lipoprotein(a) values
in different age groups up to the age of 30 years of
age, figure 5b showing the median concentrations for
the same groups according to sex, and including individ-
uals up to 93 years of age. With these data it is possible
to estimate the adult levels of lipoprotein(a) and assess
the additional risk of early onset of atherosclerotic dis-
ease by extrapolation. It can be seen from figure 5a that
serum lipoprotein(a) concentrations of 1000 mg/1 occur
during the first year of life and that values exceeding
2500 mg/1 can be measured in children under 5 years of
age. Between the ages of 6 and 30, the 84th percentile
changes from 341 to 397 mg/1, the 95th percentile from
712 to 957 mg/1 and the 99th percentile from 1234 to
1286 mg/1. Even at the age of 6 years, over 20% of all
children had lipoprotein(a) values above 300 mg/1. The
median values in figure 5b an increase in lipoprotein(a)
concentrations over the first 5 years of life, with more
or less constant median concentrations between 6 and
30 years of age. In addition, a bimodal distribution was
seen for hospitalised males with peaks around 40 and
65 years, hospitalised females having a single post-
menopausal peak.
Discussion
This study has concentrated upon the development of
(apo)lipoprotein(a) levels during the first days and




Fig. 5a 84th (Q), 95th (H) and 99th (^) percentiles and range ( )
of lipoprotein(a) concentrations in the different age groups from
birth to 30 years of age.
Eur J Clin Chem Clm Biochem 1995; 33 (No 3)
144 Wood et al.: (Apo)lipoprotein(a) in early life
200
Years of age
Fig. 5b Median lipoprotein(a) concentrations in 2700 hospitalised
individuals (1297 males, 1403 females) according to age and sex.
The results show peaks which correspond to the age groups with
the highest incidence of coronary heart disease, i.e. men between
30 and 45 years of age, and between 60 and 75 years of age, and
women after the menopause between 55 and 65 years of age. the
key to the figure is: all (O), males (S3), females (ffl).
predict whether a child has an additional risk factor,
namely that due to elevated lipoprotein(a) concentra-
tions in serum. The results of this study do not agree
fully with those of van Biervliet and co-workers (1) who
reported a significant rise in lipoprotein(a) concentra-
tions during the first week after birth, together with a
continual increase up to 180 days post partum. The
discrepancy in the lipoprotein(a) concentrations may
have been method dependent as the assay used in the
present study used two antibodies directed against apoli-
poprotein(a). Van Biervliet described an increase of
apolipoprotein B synthesis, which plateaus after around
7 days, a point which may influence the measured con-
centrations of lipoprotein(a) using an assay with one an-
tibody directed against apolipoprotein B. In theory there
is sufficient apolipoprotein B present in neonatal serum
to allow for the combination with apolipoprotein(a) to
give intact lipoprotein(a). The results presented here
using the sandwich assay with an anti-apolipoprotein B
antibody gave slightly lower results at birth and during
the first 10 days of life than the assay using two antibod-
ies directed against apolipoprotein(a), which suggests
that there is free apolipoprotein(a) in neonatal serum at
birth. As seen in figure 2a, there is no net change of
apolipoprotein concentrations in the 10 days following
birth, although individual values may change greatly as
seen in figure 2b. Previous results from the present au-
thors (5) have shown that after the perinatal period there
is no difference in the results from assays designed to
measure apolipoprotein(a) and those for lipoprotein(a).
The original idea that it may be possible to detect chil-
dren who will develop high levels of lipoprotein(a) al-
ready at birth by measuring (apo)lipoprotein(a) in cord
blood proved to be negative. The changes over the first
week of life only allowed a prediction of a value lying
in the risk range in less than 10% of all cases studied,
these being typified in figure 2b. The recommendations
of van Biervliet et al. (2), of setting a cut-off value of
1000 mg/1 for infants at risk using an enzyme immuno-
assay in blood spots to measure lipoprotein(a) in 5-7
day old infants, cannot be accepted on the basis of the
results reported in this article. The results from Wilcken
et al. (4) showed apolipoprotein(a) serum values corre-
sponding to a median level of lipoprotein(a) of 30 mg/1
and a 95th percentile value of 130 mg/1 at an range of
3-5 days, concentrations higher than those found in the
present study, namely 14.8 and 101 mg/1 respectively.
The differences may be explainable in the standardisa-
tion of the assays used.
The results from Wilcken and coworkers (4) showed a
good correlation between apolipoprotein(a) concentra-
tions at birth and after 8.5 months with a twofold
increase in concentration. The present study, although
not confirming the good correlation, also showed a me-
dian increase of 144% over a six month period.
The correlation between mother and child at birth was
similar to that found by Wilckem et al. (4), these authors
finding a correlation coefficient of 0.521 in 51 cases
measured at 8.5 months, the present study a correlation
coefficient of 0.509 for 483 cases measured at birth.
By combining the value at birth with that at around 6
months of age it appears to be possible to predict with
a good degree of accuracy, whether a child is at risk or
not. The accurate determination and documentation of
(apo)lipoprotein(a) at birth is a prerequisite, and calls
for a specific method able to measure concentrations un-
der 10, better under 5 rng/1. This rules out the relatively
unspecific nephelometric/turbidimetric methods as well
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as rocket electrophoresis and many immunoassays with
insufficient analytical lower detection limits.
A second measurement of neonatal serum lipopro-
tein(a) within the first days of life can serve to elimi-
nate falsely high concentrations due to maternal con-
tamination of cord blood. This value can also act to
stabilise the baseline measurement. An ideal time for
confirmative/alternative sampling is when blood is
taken for phenylketonuria and connatal hypothyroid-
ism. Two measurements are needed for predictive
purposes, one within the first week of life and a
second around 6 months of age.
The determination of lipoprotein(a) as in this study can
only be seen as one link, even if this is an important one,
in the diagnostic chain. Recent results from Sorensen et
al. (7) however tend to support the importance of lipo-
protein(a) as an independent risk factor, as this group
found that the early changes in vessel wall elasticity in
children with inherited hypercholesterolaemia only
correlated with serum lipoprotein(a) levels. The aim of
the authors is to apply these findings in a reverse way,
namely to check if elevated serum lipoprotein(a) levels
in children correlate with an increase in pulse-wave
velocity using a non-invasive technique of rheography
or Doppler sonography. Early changes in vessel-wall
elasticity have already been documented for diabetic
children using Doppler sonography to measure pulse-
wave velocity (8).
Even though there is no medication at present available
for correction of elevated levels of serum lipoprotein(a),
the screening of young children can lead to a register of
children .at risk, so that these can be included in a ther-
apy scheme, as soon as one becomes available, as well
as in an education project where other potential risk
factors can be minimised.
The data from hospitalised children and adults was in-
cluded not only to be able to predict the children at risk,
but to show that the peaks in the median lipoprotein(a)
concentration in hospitalised adults correspond with
those age groups with the highest risk of coronary heart
disease and myocardial infarct. These results support the
role of lipoprotein(a) as an independent risk factor for
the development of atherosclerotic disease.
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